April 2, 2018 / 11:39 AM / 8 months ago

BRIEF-Myriad Receives Pre Market Approval For Its Bracanalysis Diagnostic System In Japan

April 2 (Reuters) - Myriad Genetics Inc - ‍Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca :

* MARKET APPROVAL FOR ITS BRACANALYSIS® DIAGNOSTIC SYSTEM IN JAPAN

* MUTATED METASTATIC BREAST CANCER​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below